Vous n'êtes pas encore inscrit ?
InscriptionStrasbourg, France – Montreal, Canada – Boston, United States, January 8, 2024 – Domain Therapeutics
(“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug
candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the
appointments of Michael Gottlieb, as its Chairman of the Board of Directors, and Anthony Johnson, M.D., as
its President and Chief Executive Officer.
Michael’s appointment as Chairman follows Laurence Rulleau and Youssef Bennani, who held the role for 9
years. An industry expert with international experience leading biopharmaceutical companies, Michael is also
currently the President and Chief Executive Officer of RENOGENYX.Michael was the founding Chief
Commercial Officer of POINT Biopharma (PNT:NASDAQ), where he was responsible for global commercial
operations and market strategy and previously held leadership roles with Sanofi Genzyme.
As the new President and CEO, based in Boston, Tony succeeds Pascal Neuville who founded and successfully
led the Company for the past 15 years. Tony was previously President and CEO of Goldfinch Bio, and has been
responsible for advancing multiple products in the clinic and contributing significantly to new drug approvals.
He held leadership roles at AstraZeneca, OrbiMed Advisors, Bristol Myers Squibb and GSK. Tony holds a
medical degree and research doctorate from the University of New South Wales and achieved Fellowship of
the Royal Australasian College of Physicians in Sydney.
Mr. Michael Gottlieb, Chairman of the Board of Directors at Domain Therapeutics, said: “I am excited to
work with our board and team to make Domain a recognized leader in its field and in the US to unlock new
possibilities in GPCR targeted cancer immunotherapies.”
Dr. Tony Johnson, newly appointed President and Chief Executive Officer of Domain Therapeutics, said: “I
am honored to have the opportunity to lead at this pivotal time in the Company’s development and to work
alongside the incredible team to accelerate our innovative and uniquely positioned GPCR-derived immuno-oncology programs and expand our US market presence.”
Laurence Rulleau, Director of Domain Therapeutics, commented: “With my co-lead partners, I would like to
welcome Michael and Tony to our leadership team. Their respective expertise and track record in pioneering
and leading biopharmaceutical companies will be invaluable to the Company and will support our reach and
global focus. I would like to thank Pascal for his steadfast commitment, loyalty and service to the Company
and the Board over the last fifteen years, enabling the significant growth of the Company.”
Pascal Neuville, outgoing Chief Executive Officer of Domain Therapeutics, commented: “During my time
leading Domain Therapeutics as its CEO, we have been relentlessly dedicated to maintaining Domain as a
leader in GPCRs. I am confident that the new leadership together with the entire Domain team will continue
to build on the very promising programs developed thus far and drive the Company forward towards even
greater success to the benefit of cancer patients and their families.”
About Domain Therapeutics
Domain Therapeutics, a clinical-stage global biopharmaceutical company, focused on developing innovative
immunotherapies targeting G Protein-Coupled Receptors (GPCRs), one of the most important drug target
classes, to unlock new possibilities in cancer. As a leader in GPCRs in immuno-oncology, Domain sees cancer
differently, using a precise biomarker strategy to address the specific needs of patients based on unique
signatures of individual cancers. Two decades of solid experience in GPCR drug discovery, validated by
multiple pharma partnerships, associated to a target identification and drug discovery platform enable the
Company to enhance the understanding of cancer and deliver innovative immunotherapies to patients.
Domain’s proprietary programs include DT-7012, a Treg-depleting CCR8 antibody, DT-9045, a first-in-class
PAR2 negative allosteric modulator, and DT-9081, an EP4 receptor antagonist alongside the M1069, an
A2aR/A2b receptor antagonist identified in partnership with Merck KGaA. The company has also an
optimized pipeline of best-in-class and first-in-class GPCR targets selected through Domain’s proprietary
cross-validation drug discovery and development platform.
The Company raised €39m ($42m) in 2022 to progress preclinical and clinical development of its high-value
drug candidates to address GPCR-mediated immunosuppression. Domain is supported by leading
international venture capital firms from Europe (3B Future Health Fund, Seventure, Schroders, Omnes,
Turenne, Theodorus), Asia (Panacea and Viva) and North America (CTI Life Science, adMare).
